Promomed Group presented with plans for the development of biotechnologies to the Deputy Prime Minister of the Russian Federation Dmitry Chernyshenko

Promomed 25 October 2021

On October 22, 2021, Deputy Prime Minister of the Russian Federation Dmitry Chernyshenko visited the enterprises and infrastructure facilities of the Republic of Mordovia. During the meeting at the Department of Biotechnology and Biology of the Ogarev Mordovia State University, Promomed Group presented plans for the development of biotechnologies in pharmaceutical industry on the basis of its Biokhimik production site, as well as a project to create the Mordovian Federal Center for the Development of Biotechnologies.

«The region already has a significant groundwork for potential leadership in the field of biomedical technologies in the region: a powerful scientific potential at the Mordovia State University; research potential – at the development center of Promomed Group, industrial potential – at the Biokhimik plant. Mordovia has every chance to build a world-class biotechnology cluster and introduce Russia to the leaders of innovative pharmaceuticals. Promomed Group is ready to act as an industrial partner of such a project,» commented Petr Bely, Chairman of the Board of Directors of Promomed Group.

When asked by the Deputy Prime Minister about current developments, Kira Zaslavskaya, Director for new products at Promomed Group, gave an example of a drug based on RNA technologies. «We have managed to develop a full-cycle production technology from the producer strain to the finished dosage form. At the same time, it was important to achieve not only high productivity of the strain, but also to develop a complex system of isolation and purification of the active substance, preventing its destruction. The biotechnological nature of the drug required the development of unique methods for monitoring biological activity,» said Kira Zaslavskaya.

«The development of biotech in Russia is significant from social and scientific points of view. Successes in this area will reduce the burden on the medical support and social security systems due to the emergence of effective innovative therapies for the most significant and dangerous diseases. In addition, it will give an impetus to the development of science, increase export potential, and serve the development of related areas – from food production to digital technologies,» Petr Bely added.

The company plans to develop the direction of biotechnology and create new generation drugs in the corporate laboratories to respond to critical challenges of life and health.